The new analysis of a Pear Therapeutics-based randomized controlled trial came along another investigation that spotted early signs of treatment dropout.
Topic:
Pear's Somryst precursor improved sleep health measures among patients with chronic insomnia and depressive symptoms
More Regional News
CISA offers guide to shore up operational technology against threats
